ImmunGene Inc. Report issue

For profit Phase 2
Founded: Thousand Oaks CA United States (2007)
Status: Acquired by Spectrum Pharmaceuticals (2019) → now Repligen Corporation (2017)

Organization Overview

First Clinical Trial
2015
NCT02519270
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ImmunGene, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ign002 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1